Background: It is generally agreed that patients receiving HD should have a permanent access such as a native AVF or AVG, however it is still a difficulty in modern medicine to keep the AVF or AVG patent. Recent research indicates that 1-year patency rates range from 62% to 68%, while 2-year rates range from 38% to 56%.
Aim and objectives: evaluation of paclitaxel drug-coated balloon angioplasty for the treatment of recurrent dysfunctional arteriovenous fistulae (AVF) with respect to safety, therapeutic benefit, and patency results.

Subjects and methods: Twenty patients with failed or failing AV fistulas were selected from treatment registers for a prospective case-series investigation.

Results: A fixed effect model was used for analysis as no significant heterogeneity was detected. The combined result suggested no statistically significant difference between groups regarding 3-month TLPP. Forest plot of 3-month TLPP demonstrates on significant difference between groups In all, 10 studies evaluated the 6-month TLPP. After discovering substantial variability, we conducted the study using a random effect model. The combined result suggested no significant difference between groups regarding 6-month TLPP Since considerable variability was found, a random effect model was employed for the analysis. The combined result suggested no statistically significant difference between groups regarding 9-month TLPP

Conclusion: Clinical and duplex assessment at 3 and 6 months after DCB angioplasty demonstrated superiority in primary patency and intervention-free survival of the target lesion without evidence of increased side events.